These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9400598)

  • 21. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.
    Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG
    Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
    Beddows S; Louisirirotchanakul S; Cheingsong-Popov R; Easterbrook PJ; Simmonds P; Weber J
    J Gen Virol; 1998 Jan; 79 ( Pt 1)():77-82. PubMed ID: 9460926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.
    Spenlehauer C; Kirn A; Aubertin AM; Moog C
    J Virol; 2001 Mar; 75(5):2235-45. PubMed ID: 11160727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy.
    Wang FX; Kimura T; Nishihara K; Yoshimura K; Koito A; Matsushita S
    J Infect Dis; 2002 Mar; 185(5):608-17. PubMed ID: 11865417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of HIV-1 determinants for replication in vivo.
    Su L; Kaneshima H; Bonyhadi ML; Lee R; Auten J; Wolf A; Du B; Rabin L; Hahn BH; Terwilliger E; Mccune JM
    Virology; 1997 Jan; 227(1):45-52. PubMed ID: 9007057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between productive HIV-1 infection of macrophages and CCR5 utilization.
    Hung CS; Pontow S; Ratner L
    Virology; 1999 Nov; 264(2):278-88. PubMed ID: 10562492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
    Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
    Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
    Morikita T; Maeda Y; Fujii S; Matsushita S; Obaru K; Takatsuki K
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1291-9. PubMed ID: 9339846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
    Spenlehauer C; Saragosti S; Fleury HJ; Kirn A; Aubertin AM; Moog C
    J Virol; 1998 Dec; 72(12):9855-64. PubMed ID: 9811721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human antibodies to HIV-1 by recombinant DNA methods.
    Burton DR; Barbas CF
    Chem Immunol; 1993; 56():112-26. PubMed ID: 8452652
    [No Abstract]   [Full Text] [Related]  

  • 34. Genotypic and phenotypic characterization of a neutralization-resistant breakthrough population of HIV-1.
    Sirko DA; Ehrlich GD
    Virology; 1996 Apr; 218(1):238-42. PubMed ID: 8615028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.
    Sawyer LS; Wrin MT; Crawford-Miksza L; Potts B; Wu Y; Weber PA; Alfonso RD; Hanson CV
    J Virol; 1994 Mar; 68(3):1342-9. PubMed ID: 8107199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
    Schønning K; Jansson B; Olofsson S; Hansen JE
    J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
    Cavacini LA; Emes CL; Power J; Desharnais FD; Duval M; Montefiori D; Posner MR
    J Immunol; 1995 Oct; 155(7):3638-44. PubMed ID: 7561063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates.
    Candotti D; Rosenheim M; Huraux JM; Agut H
    J Virol Methods; 1997 Feb; 64(1):81-93. PubMed ID: 9029533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.
    Bunnik EM; Lobbrecht MS; van Nuenen AC; Schuitemaker H
    Virology; 2010 Feb; 397(1):224-30. PubMed ID: 19945135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization.
    McInerney TL; Dimmock NJ
    AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1645-54. PubMed ID: 11779352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.